Modality
Vaccine
MOA
PARPi
Target
APOC3
Pathway
T-cell
PVNMOSDBCC
Development Pipeline
Preclinical
~Oct 2021
→ ~Jan 2023
Phase 1
Apr 2023
→ Mar 2030
Phase 1Current
NCT07551956
632 pts·BCC
2023-04→2030-03·Active
632 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-03-154.0y awayPh2 Data· BCC
Trial Timeline
Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
P1/2
Active
Catalysts
Ph2 Data
2030-03-15 · 4.0y away
BCC
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07551956 | Phase 1/2 | BCC | Active | 632 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1944 | Pfizer | NDA/BLA | APOC3 | |
| Doxacapivasertib | Eli Lilly | Phase 3 | APOC3 | |
| MRK-3732 | Merck & Co | Phase 1 | TYK2 | |
| AZN-6294 | AstraZeneca | Phase 2/3 | APOC3 | |
| Zanutinib | Bristol-Myers Squibb | Phase 2/3 | APOC3 | |
| GSK-6516 | GSK | Phase 1/2 | MALT1 | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| BNT-5232 | BioNTech | NDA/BLA | TIGIT | |
| ALN-5628 | Alnylam | Phase 1/2 | APOC3 | |
| ALN-3958 | Alnylam | Phase 2 | MALT1 |